In addition, the cancer status at the time of vaccine administration influenced the levels of anti-s IgG titres as these were generally higher in patients belonging to the "watch and wait" group (median: 1040.4, IQR: 431.9-4712.7) and "complete/partial response" group (median: 913.0, IQR: 233.8-2542.5) compared to "stable/progressive disease" patients (median: 500, IQR: 155.0-1436.9), albeit the difference was not statistically significant ( I p i = 0.38) (Figure 1A). Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Violin plots depicting (A) anti-s IgG titres and (B) anti-SARS-CoV-2 neutralising activity in HM patients with prior SARS-CoV-2 infection analysed after completing the SARS-CoV-2 vaccination. In contrast, when patients were stratified according to cancer diagnosis, the anti-s IgG antibody titre was significantly higher in patients with myeloid neoplasms (median: 1896.7, interquartile range [IQR]: 818.8-4712.7) than in patients with lymphoid malignancies or plasma cell disorders (median: 715.0; IQR: 42.6-1755.9 and median: 685.3; IQR: 186.0-1602.5 respectively; I p i = 0.0031). [Extracted from the article]